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Abstract  
AIM: This study aimed to assess the prevalence and determinants of osteoporosis [lumbar spine (LS) and femoral 
neck (FN)] among patients with type 2 diabetes at King Salman Hospital.  
MATERIALS AND METHODS: One hundred seventy patients with type 2 diabetes were enrolled in this cross-
sectional study in the period from the 1st of January until the 1st of July 2015. Patient selection was based on 
self-report of the previous diagnosis by a physician, being on an antidiabetic agent, or a fasting glucose of 126 
mg/dl as per the American Diabetes Association criteria. A dual energy X-ray absorptiometry scan with the bone 
mineral density (BMD) categorization based on the WHO cut of levels of T-scores and determination of vitamin D 
levels were performed. A detailed questionnaire was used to collect demographic data. 
 
RESULTS: Out of 170 participants, 50 (29.4%) were diagnosed as having osteoporosis, while 68 (40%) were 
diagnosed with osteopenia. Age was determined as a risk factor for a decreased BMD in patients with osteopenia 
(odds ratio (OR) = 1.1, 95% confidence interval (CI) = (1.0-1.1), p = 0.039) and osteoporosis (OR = 1.1, CI = 1.0-
1.2, p < 0.001). Similarly, oral hypoglycemic agents (OHA) increased the risk of decreased BMD in osteopenia 
(OR = 2.6; CI = 1.0-6.7; p = 0.023) as well as osteoporosis, (OR = 3.8; CI = 1.3-10.9; p = 0.013), while vitamin D 
deficiency increased the risk of osteopenia OR = 3.0; CI = 1.2-7.2; p = 0.012). Increased BMI decreased the risk 
of both osteopenia and osteoporosis (OR = 0.9; CI = 0.9-0.99; p = 0.031 vs. OR = 0.9; CI = 0.80-0.95; p = 0.003). 
CONCLUSION: Advanced age, OHA and vitamin D deficiency are determinants of decreased BMD in Saudi 
women with type 2 diabetes, while an increased BMI protects against low BMD. 
 
 
 
 
 
 
 
Introduction 
 
Diabetes mellitus has become a major 
problem worldwide, and it is speculated that the 
burden of such a problem will reach 7.7% by the year 
2030 [1]. The Arabian Gulf area is one of the most 
affected regions where the problem of obesity is 
expected to continue to rise, and five of the region 
states are likely to be among the ten countries with 
the highest diabetic morbidity by the year 2030 [1, 2]. 
Reports about the prevalence of diabetes mellitus in 
Saudi Arabia estimate the current prevalence to be 
around 17% with expectations that it will peak at more 
than 20% by the year 2030 [3].
 
Osteoporosis is defined by the presence of 
both reduced bone mass and altered bone quality, 
along with micro-architectural abnormalities, leading 
to decreased bone strength and probably pathological 
fractures [4]. The risk factors for osteoporosis include 
advanced age, use of glucocorticoids, nutritional 
factors, low body mass index and genetic factors [5-
7]. According to a recent report, more than one-third 
of the healthy Saudi individuals were found to have 
osteoporosis [8].
 
Despite the presence of different reports 
describing skeletal disorders among patients with 
diabetes, controversy remains concerning the risk of 
osteoporosis and its clinical importance among these 
patients [9]. Some studies have shown osteopenia 
and frequent bone fractures among type 1 diabetics; 
nonetheless, evidence demonstrating this risk among 
type 2 diabetics remains elusive [10,11]. Evidence of 
high bone mineral density and body mass index (BMI) 
shown in previous epidemiological studies proposing 
a reduction in fracture risk led to the assumption that 
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type 2 diabetics could have a lower risk of 
osteoporosis [12]. However, recent evidence suggests 
that the fracture risk among patients with type 2 
diabetes is higher, whether high bone mineral density 
(BMD) is present or not [10, 13]. Both type 1 and 2 
diabetes mellitus is regarded as a risk factor within the 
Fracture Risk Assessment Tool (FRAX-algorithm), 
which is commonly used to examine the probability of 
fracture [14].
 
The coexistence of osteoporosis and type 2 
diabetes mellitus is common among the elderly 
population, putting this group at higher risk of bone 
fracture. Additional investigations are desirable to 
explore possible risk factors and predictors of 
osteoporosis among elderly.  
The aim of the current study was to assess 
the prevalence and of risk factors for osteoporosis 
(lumbar spine (LS) and femoral neck (FN) BMD< −2.5 
SD T-score) in a cohort of consecutive female patients 
with type 2 diabetes mellitus. 
 
 
 
Patients and Methods 
 
Patients 
This is a cross-sectional study where we 
included a total number of 170 females with type 2 
diabetes. The patients were recruited consecutively 
from the outpatient clinic of King Salman Hospital, 
Riyadh, Saudi Arabia after obtaining their consent. 
Data was gathered using a structured questionnaire 
during the follow-up visits for the control of diabetes 
between the 1
st
 of January until the 1
st
 of July 2015. 
The questionnaire included the patients' demographic 
data, history of comorbidities, medicaments history 
including vitamin D supplementation and the anti-
diabetic agents along with an evaluation of proposed 
osteoporosis risk factors such as the history of 
immobility, exercise, and previous fragility fracture. 
 
 
Methods 
The diagnosis of type 2 diabetes was based 
on reviewing the patients' outpatient clinic medical 
records of the Department of Internal Medicine, 
Endocrinology, at King Salman Hospital. The sample 
size was calculated using the Epi- info statistical 
calculator utilising the formula
 
Sample size n = [DEFF*Np(1-p)]/ [(d
2
/Z
2
1-α/2*(N-1)+p*(1-p)] = 167 
We used a population size (for finite 
population correction factor or fpc) (N):1000000, and 
we assumed that the prevalence of the disease 
among the Saudi population is 34% based on 
previous publications, and we calculated our sample 
size with 5% limit of confidence and an 80% study 
power. 
Diabetes was considered based on self-report 
of diabetes previously diagnosed by a physician in the 
medical records, if the patient was already taking 
antidiabetic medication or by obtaining a fasting 
glucose reading of126 mg/dl as per the American 
Diabetes Association criteria [16]. Patients presenting 
with type 1 diabetes mellitus were excluded from the 
study. Measurement of BMD was carried at the LS 
(L2–L4, LS) and the right and left femur necks using 
dual-energy x-ray absorptiometry (DXA) by a Hologic 
4500 bone densitometer. We compared our patient's 
measurements with age- and sex-matched normal 
reference values provided by Hologic for Caucasian 
populations. BMD categorization was based on the 
cut-off levels of T-scores set by the WHO [where 
osteoporosis is diagnosed as a (T-score < −2.5 SD), 
osteopenia (T-score from −1 to −2.5 SD) and normal 
(t-score > −1 SD)] [17]. 
 
Ethical approval 
Ethical approval for the current study was 
obtained from the Ethics Committee of King Fahad 
Medical city. All participants and patients were 
enrolled in the study after signing a written informed 
consent. 
 
Statistical analysis 
SPSS for Windows (version 20.0) was used 
for analysis after data were entered into computer 
database. To compare the continuous variables (after 
checking for normality and proportions between the 
different groups of BMD), one –way ANOVA was used 
as well as 
2
 tests. Multinomial logistic regression was 
used when the p value of variables of the one-way 
ANOVA and 
2 
test were less than < 0.2, with BMD 
groups entered as the dependent variables and age, 
body mass index (BMI), history of previous fragility 
fracture, vitamin D deficiency, history of type 2 
diabetes mellitus and use of oral hypoglycemic agents 
as independent variables. On calculating the odds 
ratios and 95 % confidence interval, a p value was 
regarded significant if it is < 0.05. 
 
 
 
Results 
 
The general characteristics of the 170 
participants are shown in Table 1. Around one-third 
(29.4%) of our patients were found to have 
osteoporosis, while 68(40%) of the enrolled women 
were found to have osteopenia.
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Table 1: Showing the characteristics of the study population 
Variable  N = 170 and % 
Age in years (mean ± SD) 56.3 ± 8.5 
BMI (mean ± SD) 32.2 ± 6.2 
Insulin 27 ± 19% 
Oral Hypoglycaemics 85 ± 59.9% 
Osteoporosis 50 ± 29.4% 
Osteopenia 68 ± 40% 
Immobility  3 ± 1.8 
Exercise 17 ± 10% 
Myopathy 18 ± 10.6% 
Use of steroids 1 ± 0.6% 
Use of Calcium 86 ± 50.6% 
Estrogen deficiency 29 ± 17.1% 
Smoking 2 ± 1.2% 
Early menopause 9 ± 5.3% 
Alcohol 0 
Rheumatoid Arthritis 0 
Vitamin D supplement 84 ± 49.4% 
Kyphosis 3 ± 1.8% 
Frax score Low  116 ± 68.2% 
 Moderate  34 ± 20% 
 High  20 ± 11.8% 
 
Out of the enrolled 170 women, 116 (68.2%) 
scored low FRAX index, 34 (20%) had intermediate 
and 20 (11.8%) women a high FRAX index score. Use 
of oral hypoglycemic medication was confirmed in 
59.9% of patients. The prevalence of osteoporosis 
based on location is shown in Table 2. The 
comparison regarding the prevalence of osteoporosis 
between the different groups shows that it is detected 
more frequently on examining the vertebrae (28%).  
Table 2: Prevalence of osteopenia and osteoporosis in 
postmenopausal diabetic Saudi women according to bone 
mineral density and WHO criteria 
Variable Normal n (%) Osteopenia n (%) Osteoporosis n (%) 
Vertebrae 56 (32.9) 66 (38.8) 48 (28.3) 
Right femur 114 (67.1) 50 (29.4) 6 (3.5) 
Left Femur 115 (67.6) 49 (28.8) 6 (3.5) 
 
While there was no significant difference in 
the distribution of cases who are on insulin, immobile, 
those who were exercising, or suffering myopathy, the 
age, the prior history of fragility fracture, use of oral 
hypoglycemic agents and vitamin D deficiency were 
significantly higher in the osteoporosis group 
compared to the group with normal BMD reflecting 
that they were risk factors for low BMD. To the 
contrary, BMD was found to decrease with reductions 
in BMI (see Table 3). 
Table 3: Univariate analysis comparing the characteristics of 
the study population, between the bone mineral density groups 
among Saudi women 
Variables  
Normal 
(52) 
P 
value 
Osteopenia  
N   (68) 
P value 
Osteoporosis 
N  (50) 
P value 
Age in years 
(mean(sd)) 
52.3 (7) 0.034 56.2 (7. 5) 0.050 60.5 (9.2) <0.001 
BMI(mean(sd)) 34.2 (6) 0.040 32.1 (6.1) 0.129 30.2 (6.2) 0.005 
Insulin 5 0.351 13 0.110 9 0.278 
Oral 
Hypoglycaemics 
33 0.018 34 0.015 18 0.038 
Immobility 1 1.000 0 * 2 0.263 
Exercise 3 0.872 7 0.475 7 0.381 
Myopathy 5 0.093 6 0.762 7 0.641 
Vitamin D 
deficiency 
31 0.010 24 0.012 29 0.011 
Calcium intake 24 0.015 40 0.012 22 0.010 
Use of steroids 0 0.145 0 * 1 0.292 
Early Menopause 0 0.999 5 <0.001 4 0.140 
Caffeine 15 0.562 0 0.337 0 0.499 
*This parameter is set to zero because it is redundant. 
 
Multinomial analyses (Table 4) showed that 
age was a risk factor for a decreased BMD for both 
osteopenia (odds ratio (OR) = 1.1, 95% confidence 
interval (CI) = (1.0-1.1), p = 0.039) and osteoporosis 
(1.1) (1.0-1.2), p = <0.001). Similarly use of oral 
hypoglycemic agents increased the risk of decreased 
BMD in cases with osteopenia (2.6) (1.0-6.7), p = 
0.032) as well as with osteoporosis, (3.8) (1.3-10.9), p 
= 0.013), while vitamin D deficiency increased the risk 
of osteopenia alone (3.0) (1.3-7.2), p = 0.012). 
Table 4: The Odds ratio (95% confidence interval), P value for 
multinomial analyses where normal bone mineral density was 
the reference  
Variables  Osteopenia (N = 91) Osteoporosis (N = 55) 
 OR CI P 
value 
 OR CI P 
value 
Age in years 
(mean ± sd) 
56.2 ± 7. 5 1.1 1.0-1.13 0.039 60.5 ± 9.2 1.1 1.0-1.2 <0.001 
BMI (mean ± 
sd) 
32.1 ± 6.1 0.9 0.9-0.99 0.031 30.2 ± 6.2 0.9 0.80-0.95 0.003 
Oral Hypogly-
caemics 
34 2.6 1.0-6.7 0.023 18 3.8 1.3-10.9 0.013 
Vitamin D 
deficiency 
24 3.0 1.2-7.2 0.012 29 1.5 0.5-3.9 0.502 
 
Calcium was set to zero because it was 
redundant. On the other side high BMI decreased the 
risk of both osteopenia and osteoporosis (0.9) (0.9-
0.99), p = 0.031, 0.9 (0.79-0.95), p = 0.003 
respectively.  
 
 
Discussion 
 
The prevalence of osteoporosis among the 
diabetic population we studied was 29.4%, which is 
slightly less than what was previously reported in 
Saudi Arabia (34%) [8]. This could be explained in the 
context of what has been described by Vestergaard in 
his study which showed that patients with type 2 
diabetes tend to have a higher BMD. Nonetheless, 
they have a higher fracture risk [18]. Another 
important finding reflected by the current study is the 
agreed upon fact regarding the inverse relation 
between age and BMD in cases of osteopenia and 
osteoporosis [19-21] which is likely attributed to the 
mobilization of calcium from bone. According to the 
present study, the advancement in age increased the 
likelihood of osteopenia and osteoporosis with an 
odds-ratio of 1.1. An explanation for this weak effect is 
the background of our patients since it is believed that 
type 2 diabetes is associated with a higher BMD as 
has been mentioned before. The use of oral 
hypoglycemic agents was another predictor for the 
development of osteopenia or osteoporosis as 
indicated by the current study. Based on our findings, 
patients on oral hypoglycemic medications have a 
nearly three times risk of developing osteopenia and 
more than four times chance of becoming 
osteoporotic. These findings are in agreement with 
what was demonstrated by Billington et al. in their 
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meta-analysis regarding the effects of 
thiazolidinediones on BMD [22]. Moreover, it is known 
that metformin is associated with a higher incidence of 
bone fractures [23]. It is worth mentioning that our 
results included oral hypoglycemic agents with no 
reference to a particular type of the oral hypoglycemic 
agents. Kumar et al. found that oral hypoglycemic 
agents did not affect the BMD after usage for three 
years [24]. The current study showed that BMI 
protects against a decrease in BMD, such a finding 
has been claimed by Chen et al. in their study among 
elderly type 2 diabetic men [25], nonetheless, other 
researchers declared different findings concerning the 
relation between BMI and BMD [26].
 
Expectedly, vitamin D deficiency decreased 
BMD in diabetic patients we studied, as has been 
previously shown in another study [27]. In contrast to 
our findings, Kota et al. found no direct relation 
between Vitamin D levels and BMD despite showing a 
significant association with the parathormone levels 
[28]. However, the effect of vitamin D deficiency was 
seen in osteopenic patients only, a finding that might 
be explained by supplementation of some of the 
osteoporotic patients with vitamin D preparations. We 
have to acknowledge the fact that more details about 
the hypoglycemic agents would have led to better 
conclusions. Including controls would have helped to 
delineate the type 2 diabetes risk of osteoporosis. 
One more important limitation to our study is the fact 
that it has been conducted among a female population 
and thus it is difficult to extrapolate our results to the 
whole community. 
In conclusion, the current study showed that 
advanced age, oral hypoglycemic agents and vitamin 
D deficiency are risk factors for a decreased bone 
mineral density, while an increased BMI was found to 
guard against a reduction in BMD in Saudi women. A 
case-control study on a larger scale is recommended 
and is expected to describe the risk factors and the 
relation between type 2 diabetes and osteoporosis in 
a more clear way.
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